---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-006977"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2022-01-24T23:59:59+00:00"
generated_at: "2026-06-27T16:11:13.602158+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MaxCyte preliminary Q4 rev >$10M (+17% YoY); FY rev >$33.7M (+28%); adds 4 SPLs in 2021

## Summary
- Q4 2021 preliminary revenue >$10.0M (up from $8.5M in Q4 2020); core business revenue grew at least 37%.
- Full year 2021 revenue >$33.7M (up from $26.2M in 2020); program-related revenue $2.5M (vs $3.3M in 2020).
- Installed base grew to >500 instruments (from >400); 15 SPLs covering >95 programs, over 15% in clinic.
- Precommercial milestone potential from SPLs exceeds $1.25B (up from >$950M in 2020).
- New SPLs: Nkarta, Myeloid Therapeutics, Celularity, Sana Biotechnology; ExPERT VLx instrument launched.

## SEC filing metadata
- accession: 0001104659-22-006977
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2022-01-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000110465922006977/0001104659-22-006977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000110465922006977/tm224229d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-006977
- JSON: https://secwatch.observer/filing/0001104659-22-006977.json
- Plain text: https://secwatch.observer/filing/0001104659-22-006977.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.